Researchers at our laboratories are developing a bivalent hookworm vaccine that will provide protection against Necator americanus, an intestinal parasite that infects hundreds of millions of people worldwide. The vaccine will be comprised of two recombinant antigens, Na-GST-1 and Na-APR-1, enzymes involved in the parasite's digestion of host blood. Monovalent vaccines developed by our researchers with Na-GST-1 and Na-APR-1 as single antigens are currently undergoing various Phase 1 clinical trials. Na-GST-1 and Na-APR-1 have completed Phase 1, first-in-humans safety trials, becoming the first-ever hookworm vaccines to complete clinical trials. Na-GST-1 study record details Na-APR-1 study record details
Currently researchers at George Washington University are conducting a challenge test to determine the efficacy of Na-GST-1, infecting hookworm-naïve adults with hookworm larvae. Study record details
Other ongoing and pending safety trials:
Other current activities include stability testing for both Na-GST-1 and Na-APR-1.